Due to the poor prognosis of tumors harboring TP53 mutations, targeting p53 is an attractive strategy for cancer therapies, such as by restoring the normal transcriptional activity of p53, directly repressing mutant p53 levels, and inhibiting transcriptional targets of mutant p53 [7,8]. This evidence concerns the gene TP53 and cancer.